Chest ACCP Career Connection
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (11)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lam, C. F.
Right arrow Articles by Filion, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lam, C. F.
Right arrow Articles by Filion, P.
(Chest. 2003;123:869-874.)
© 2003 American College of Chest Physicians

Two Aerosolized Nitric Oxide Adducts as Selective Pulmonary Vasodilators for Acute Pulmonary Hypertension*

Chen F. Lam, MD; Peter V. van Heerden, PhD, FCCP; Kenneth F. Ilett, PhD; Paul Caterina, PhD and Pierre Filion, MSc

* From the Department of Pharmacology (Drs. Lam and Ilett), University of Western Australia, Crawley; Department of Intensive Care (Dr. van Heerden), Sir Charles Gairdner Hospital, Perth; and Department of Anatomical Pathology (Dr. Caterina and Mr. Filion), The Western Australia Center for Pathology and Medical Research, Nedlands, Australia.

Correspondence to: Chen F. Lam, MD, Department of Pharmacology, University of Western Australia, Crawley, WA 6009, Australia; e-mail: cflam{at}cyllene.uwa.edu.au

Study objectives: To determine the selective vasodilatory effects of two inhaled "NONOate" aerosols in a closed chest pig model of acute pulmonary hypertension (APH).

Methods: APH was induced by IV infusion of the prostaglandin H2/thromboxane A2 receptor agonist (U46619). Aerosolized diethylenetriamine nitric oxide (NO) adduct (DETA/NO, n = 4), dipropylenetriamine NO adduct (DPTA/NO, n = 4) [60 µmol each], or placebo (n = 4) was delivered via the trachea. Hemodynamic parameters and blood samples were measured before and after inhalation therapy.

Results: Compared to control animals, pulmonary vascular resistance and pulmonary arterial pressure were significantly reduced from 10 to 105 min after DETA/NO administration and from 10 to 45 min after DPTA/NO aerosol administration (p < 0.05). Both aerosols had no significant effect on systemic vascular resistance or systemic BP. Serum nitrite significantly increased after the inhalation of both NONOates (p < 0.01). There was a tendency for reduced intrapulmonary shunting, particularly after treatment with DETA/NO.

Conclusion: Both DETA/NO and DPTA/NO administered as aerosols selectively reduced pulmonary hypertension induced by U46619.

Key Words: ARDS • NONOates • pulmonary hypertension • selective pulmonary vasodilators




This article has been cited by other articles:


Home page
 J. Appl. Physiol.Home page
B. L. Sandifer, K. L. Brigham, E. C. Lawrence, D. Mottola, C. Cuppels, and R. E. Parker
Potent effects of aerosol compared with intravenous treprostinil on the pulmonary circulation
J Appl Physiol, December 1, 2005; 99(6): 2363 - 2368.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American College of Chest Physicians.